Full history for every metric is available with a Kvantra account
Uscom Limited (UCM.AX)
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 3 | 4 | 3 | 3 | 4 | 3 | 1 |
| Operating profit | AUD m | -4 | -4 | |||||
| Net profit | AUD m | -1 | -1 | -2 | -3 | -2 | -3 | -1 |
| EPS reported | AUD | -0.02 | -0.01 | |||||
| Operating cashflow per share | AUD | -0.01 | -0.01 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.01 | -0.01 | |||||
| Free cash flow | AUD m | -3 | -3 | |||||
| Net debt | AUD m | 1 | 0 | |||||
| Book value equity | AUD m | - | 0 | |||||
| Book value per share | AUD | -0.00 | 0.00 | |||||
| Number of shares | m | 185.5 | 260.15 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -76.24 | 17.08 | |||||
| P/S LTM | x | 1.13 | 2.56 | |||||
| P/FCF LTM | x | -1.07 | -1.11 | |||||
| EV/EBITDA LTM | x | -1.38 | -1.11 | |||||
| EV/Sales LTM | x | 1.63 | 2.57 | |||||
| Earnings Yield LTM | % | -113.33% | -41.42% | |||||
| FCF Yield | % | -93.48% | -90.29% | |||||
| Quality | ||||||||
| ROE | % | 8640.5% | -1788.6% | |||||
| ROIC | % | -158.20% | -1724.8% | |||||
| Operating margin | % | -144.62% | -287.91% | |||||
| Gross margin | % | 86.48% | 8.56% | |||||
| FCF/Sales | % | -105.64% | -230.76% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -30.80% | -66.36% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.20 | -133.63 | |||||
| Net Debt/EBITDA | x | -0.42 | -0.01 | |||||
| EBIT/Net interest | x | -27.85 | -15.72 | |||||
| Net debt/market cap | % | 20.84% | 0.62% | |||||
| Net debt/Equity | x | - | 0.11 | |||||
| Gross debt/equity | x | - | 0.12 | |||||
Company overview
Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-invasively assess hemodynamic and cardiovascular performance. Also available is the BP+, a central blood pressure monitor employing supra-systolic oscillometry to gauge blood pressure and its waveforms both centrally (at the heart) and peripherally (in the arm). The company also produces the SpiroSonic, an ultrasound-based multi-path system for evaluating pulmonary function. Further expanding its offerings, Uscom presents the SpiroSonic AIR, a digital multipath ultrasonic spirometer featuring an integrated viral disinfection system capable of neutralizing pathogens like COVID and tuberculosis, alongside other respiratory equipment. Uscom's solutions are delivered to hospitals and various healthcare facilities via a broad network of distribution alliances. Established in 1999, the firm initially operated as Uscom Pty Limited before adopting the name Uscom Limited in October 2003. Its main corporate office is situated in Sydney, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Uscom Limited (UCM.AX)
Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-invasively assess hemodynamic and cardiovascular performance. Also available is the BP+, a central blood pressure monitor employing supra-systolic oscillometry to gauge blood pressure and its waveforms both centrally (at the heart) and peripherally (in the arm). The company also produces the SpiroSonic, an ultrasound-based multi-path system for evaluating pulmonary function. Further expanding its offerings, Uscom presents the SpiroSonic AIR, a digital multipath ultrasonic spirometer featuring an integrated viral disinfection system capable of neutralizing pathogens like COVID and tuberculosis, alongside other respiratory equipment. Uscom's solutions are delivered to hospitals and various healthcare facilities via a broad network of distribution alliances. Established in 1999, the firm initially operated as Uscom Pty Limited before adopting the name Uscom Limited in October 2003. Its main corporate office is situated in Sydney, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free